What does Pappas Capital invest in?
Pappas Capital invests most often at Series A and Series B (91% of the rounds on record), in sectors such as Molecules, Pharmaceuticals and Medicine.

United States · Investor
Last cheque observed Oct 2026; 12 cheques on record.
Deploying nowVC firm
Follow Pappas Capital and see its new cheques in your feed.Start following
2 cheques in the last 12 months
Mostly Series A and Series B: 91% of its rounds
For 32 years Pappas Capital has been investing in and building innovative companies that are developing the next generation of life science products and technologies.From their own website
Every round we can evidence, newest first12 appearances
2 rounds
1 round
5 rounds
3 rounds
1 round
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Named by the firm itself, on a filing, its Form ADV or its company registration2 named
We also hold 8 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
From the firm's own filings with the SEC, which it must file accurately by law
From their own portfolio page (on their website)
bioNVCAWebtoffeenc-biotech
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
The investors most often in the same rounds as Pappas Capital. A count of rooms they were both in, not a relationship either has claimed.
The latest companies Pappas Capital put money into.
Pappas Capital invests most often at Series A and Series B (91% of the rounds on record), in sectors such as Molecules, Pharmaceuticals and Medicine.
12 investments on record, 2 of them in the last 12 months. The most recent was in Oct 2026.
Its most recent investments on record: Altay Therapeutics, Inc. (Series A, Oct 2026), Breye Therapeutics (Series A, Sept 2026) and Reneo Pharmaceuticals (Series A, May 2019).
The median round it joins is $52M.
Rarely, if at all: none of its 12 investments on record names it as the lead.
Most of the companies it backs are in the United States (75%), Denmark (8%) and Canada (8%).
Yes: it is actively investing, with 2 investments in the last 12 months.
Most often Alexandria Real Estate Equities (2 rounds together), Hatteras Venture Partners (2 rounds together) and New Enterprise Associates (2 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it